Selexis, IAVI Expand HIV Vaccine Pact
Selexis, a Geneva, Switzerland-based life sciences company focused on mammalian cell-line generation, has expanded its collaboration with the International AIDS Vaccine Initiative (IAVI) to include two additional service agreements, making three in total including their original agreement. Financial terms were not disclosed.
Under the additional two agreements, Selexis will develop research cell banks to manufacture multiple human immunodeficiency virus (HIV) envelope proteins engineered by scientists at IAVI’s Neutralizing Antibody Center (NAC) at The Scripps Research Institute (TSRI) and other parts of TSRI to help generate neutralizing antibodies against HIV through vaccination. Previously, Selexis worked with IAVI on another engineered HIV envelope protein, also being developed by IAVI’s NAC at TSRI and other parts of TSRI, to increase cell line productivity using the Selexis CHO-Mplus libraries.